Epstein-Barr Virus Infections Clinical Trial
Official title:
A Pilot Study in the Treatment of Refractory Epstein-Barr Virus (EBV) Infection With Related Donor EBV Cytotoxic T-Lymphocytes in Children, Adolescents and Young Adult Recipients
Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01256853 -
Modified Vaccinia Ankara (MVA) Vaccine Study
|
Phase 1 | |
| Completed |
NCT00070785 -
Protein Studies of the Epstein-Barr Virus in Ethnically Diverse Populations
|
N/A | |
| Recruiting |
NCT01248598 -
The Prevelance Rate of Human Cytomegalovirus (HCMV), Epstein-Barr Virus (EBV) and Human Herpes Virus (HHV-6) in a Saliva of the Patient With Periodantitis
|
N/A | |
| Completed |
NCT00701922 -
Surveillance Study of Viral Infections Following Lung Transplantation
|
N/A | |
| Recruiting |
NCT02580539 -
A Study of the Safety and Efficacy of EBV Specific T-cell Lines
|
Phase 1/Phase 2 | |
| Completed |
NCT03546101 -
Early Detection of Epstein-Barr Virus Related Disease.
|
||
| Recruiting |
NCT05183490 -
R-MVST Cells for Treatment of Viral Infections
|
Phase 1 | |
| Completed |
NCT00058812 -
Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts
|
Phase 1 | |
| Completed |
NCT01094405 -
Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy
|
Phase 2 | |
| Terminated |
NCT05305040 -
Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
|
Phase 2/Phase 3 | |
| Completed |
NCT02335437 -
Chronic Fatigue Following Acute Epstein-Barr Virus Infection in Adolescents
|
N/A | |
| Completed |
NCT06002802 -
Study on Infectious Mononucleosis in Munich
|
||
| Recruiting |
NCT04507477 -
Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial
|
Phase 1/Phase 2 | |
| Completed |
NCT00963248 -
EBV Infection as a Risk Factor for PTLD in Pediatric and Adult Renal Transplant Recipients
|
N/A | |
| Enrolling by invitation |
NCT06027879 -
Anti-viral T-cell Therapy by Gamma Capture
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05592626 -
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02715752 -
A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin
|
N/A | |
| Completed |
NCT01070797 -
Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)
|
Phase 1 | |
| Completed |
NCT00058604 -
Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).
|
Phase 1 | |
| Completed |
NCT00058591 -
Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs)
|
Phase 1 |